February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology

New Orleans, LA—The FIRST (Frontline Investigation of Rev­limid plus Dexamethasone versus Standard Thalidomide) trial in transplant-ineligible patients demonstrated the benefit of continuous lenalidomide (Revlimid).
New Orleans, LA—Emerging agents for multiple myeloma (MM) are promising as future treatment options. The arsenal now includes many new classes of agents beyond the standard immunomodulatory drugs (IMiDs) and proteasome inhibitors. Here is a look at the key studies presented at ASH 2013.
New Orleans, LA—Genomic sequencing and protein analysis are providing new insights into hematologic malignancies, paving the way for treatment advances and personalized medicine. At the Presidential Symposium at ASH 2013, the potential use of genomics in clinical decision-making was explored.
New Orleans, LA—Treatments for non-Hodgkin lymphoma (NHL) may take a new turn with several inhibitors of the PI3 kinase (PI3K) nearing approval. PI3K-delta signaling is critical for B-cell activation, proliferation, and survival, and it is hyperactive in many B-cell malignancies.
New Orleans, LA—In patients with transformed indolent lymphoma (TrIL) who achieve a complete metabolic remission, surveillance scanning with positron emission tomography–computed tomography (PET-CT) is of limited clinical benefit, based on results of a retrospective analysis presented at ASH 2013.
New Orleans, LA—Findings from 2 major studies presented at ASH 2013 indicate that the longer the maintenance period, the greater the duration of progression-free survival (PFS) in follicular lymphoma (FL); however, overall survival (OS) was still not improved, even at 6 years of follow-up.
Hematologic cancers continue to gain awareness for payers. This is a result of the number of novel therapies recently approved by the US Food and Drug Administration to treat cancers that have few alternatives, as well as the growing number of expanded indications and use of combination therapies.
New Orleans, LA—Long-term analyses of patients with high-risk myelofibrosis show continued efficacy of ruxolitinib in reducing mortality risk compared with conventional therapy. The efficacy of ruxolitinib on outcomes was not affected by the presence of detrimental genetic mutations.
New Orleans, LA—Infection and fever without a source are the most common causes of readmission after allogeneic hematopoietic stem-cell transplantation (HSCT), and being readmitted within 30 days of discharge is associated with a lower 5-year overall survival (OS) rate, according to Laura Spring, MD, of the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston.
New Orleans, LA—For the treatment of leukemia and other hematologic malignancies, the pool of donors for hematopoietic stem-cell transplant can be greatly expanded through the use of HLA-haploidentical, or half-matched, donors, according to researchers who reported good outcomes at ASH 2013.
Page 3 of 4
Results 21 - 30 of 32
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME